Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 10/20 | 0.73 |
| ▸ | MEN1 | O00255 | 9/20 | 0.73 |
| ▸ | RAB9A | P51151 | 4/20 | 0.73 |
| ▸ | NPC1 | O15118 | 3/20 | 0.73 |
| ▸ | MITF | O75030 | 2/20 | 0.73 |
| ▸ | POLB | P06746 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 8/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.60 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9134339 | 0.93 | KMT2A (0.83) | KMT2AMEN1RAB9ANPC1MITF | |
| SCHEMBL8572381 | 0.93 | KMT2A (0.83) | KMT2AMEN1RAB9ANPC1MITF | |
| SCHEMBL23898948 | 0.93 | KMT2A (0.83) | KMT2AMEN1RAB9ANPC1MITF | |
| SCHEMBL28612321 | 0.92 | MEN1 (0.74) | KMT2AMEN1RAB9ANPC1MITF | |
| SCHEMBL296991 | 0.89 | MEN1 (0.68) | KMT2AMEN1RAB9ANPC1MITF | |
| SCHEMBL27903465 | 0.89 | KMT2A (0.75) | KMT2AMEN1RAB9ANPC1MITF | |
| SCHEMBL16367722 | 0.88 | KMT2A (0.76) | KMT2AMEN1RAB9ANPC1MITF | |
| SCHEMBL24213121 | 0.88 | KMT2A (0.76) | KMT2AMEN1RAB9ANPC1MITF | |
| SCHEMBL7881346 | 0.87 | KMT2A (0.79) | KMT2AMEN1RAB9ANPC1MITF | |
| SCHEMBL7696438 | 0.87 | KMT2A (0.79) | KMT2AMEN1RAB9ANPC1MITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115090-B2 | Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2015-08-25 | — | — | US | claimed |
| US-20070225373-A1 | Zn2Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2007-09-27 | — | — | US | claimed |
| EP-1696898-A2 | ZN 24 -CHELATING MOTIF-TETHERED SHORT-CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2006-09-06 | — | — | EP | claimed |
| WO-2005055928-A2 | ZN2+ -CHELATING MOTIF-TETHERED SHORT -CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2005-06-23 | — | — | WO | claimed |
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB (SE) | 2021-03-04 | — | — | US | disclosed |
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENT AB (SE) | 2017-01-26 | — | — | US | disclosed |
| EP-1696898-B1 | ZN 2+ -CHELATING MOTIF-TETHERED SHORT-CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS | UNIV OHIO STATE RES FOUND (US) | 2015-11-18 | — | — | EP | disclosed |
| US-9115090-B2 | Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2015-08-25 | — | — | US | disclosed |
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB | 2014-02-20 | — | — | US | disclosed |
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB | 2014-02-20 | — | — | US | disclosed |
| US-8318808-B2 | Zn2+chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-11-27 | — | — | US | disclosed |
| WO-2011143314-A1 | COMPOSITIONS AND METHODS FOR REDUCING PROLIFERATION AND VIABILITY OF LYMPHOBLASTOID CELLS | ARNO THERAPEUTICS, INC (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011103563-A1 | METHODS AND COMPOSITIONS FOR INHIBITING AND PREVENTING THE GROWTH OF MALIGNANT MAST CELLS | ARNO THERAPEUTICS, INC (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20090137679-A1 | ZN2+Chelating Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase Inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-05-28 | — | — | US | disclosed |
| US-20080015190-A1 | Inhibitors of Histone Deacetylase | MERCK SHARP & DOHME CORP. | 2008-01-17 | — | — | US | disclosed |
| US-20080015190-A1 | Inhibitors of Histone Deacetylase | MERCK SHARP & DOHME CORP. | 2008-01-17 | — | — | US | disclosed |
| US-20070225373-A1 | Zn2Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2007-09-27 | — | — | US | disclosed |
| EP-1696898-A2 | ZN 24 -CHELATING MOTIF-TETHERED SHORT-CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2006017214-A2 | INHIBITORS OF HISTONE DEACETYLASE | MERCK & CO., INC. (US) | 2006-02-16 | — | — | WO | disclosed |
| WO-2005055928-A2 | ZN2+ -CHELATING MOTIF-TETHERED SHORT -CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | KMT2A 223/4885MEN1 4342/4885RAB9A 3597/4885 |
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | KMT2A 223/4885MEN1 4342/4885RAB9A 3597/4885 |
| US-20070225373-A1 | Zn2Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase | HDAC1, BAZ2B, HDAC11 | KMT2A 118/4885MEN1 4539/4885RAB9A 4723/4885 |
| US-20080015190-A1 | Inhibitors of Histone Deacetylase | HDAC5, HDAC1, HDAC4 | KMT2A 55/4885MEN1 3547/4885RAB9A 2502/4885 |
| US-20090137679-A1 | ZN2+Chelating Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase Inhibitors | HDAC1, HDAC9, HDAC3 | KMT2A 113/4885MEN1 4783/4885RAB9A 4523/4885 |
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | KMT2A 223/4885MEN1 4342/4885RAB9A 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.